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Abstract
In the last decades, several steps have been made aiming at rendering human IVF more successful on one side,
more tolerable on the other side. The “mild” ovarian stimulation approach, in which a lower-than-average dose of
exogenous gonadotropins is given and gonadotropin treatment is started from day 2 to 7 of the cycle, represents
a significant step toward a more patient’s friendly IVF. However, a clear view of its virtues and defects is still
lacking, because only a few prospective randomized trials comparing “mild” vs. conventional stimulation exist, and
they do not consider some important aspects, such as, e.g., thawing cycles. This review gives a complete
panorama of the “mild” stimulation philosophy, showing its advantages vs. conventional ovarian stimulation, but
also discussing its disadvantages. Both patients with a normal ovarian responsiveness to exogenous gonadotropins
and women with a poor ovarian reserve are considered. Overall, we conclude that the level of evidence
supporting the use of “mild” stimulation protocols is still rather poor, and further, properly powered prospective
studies about “mild” treatment regimens are required.
Background
Since the early ages of human in-vitro fertilization (IVF)
it turned out clearly that the effectiveness of the proce-
dure when performed on a natural, single-egg cycle was
very limited. An important step toward getting better
results was represented by the availability of medications
able to induce multiple ovulation. For several years, and
until now, ovarian stimulation with exogenous hor-
mones has been widely applied with the aim of increas-
ing the number of oocytes available for fertilization [1].
For years pharmaceutical companies have been compet-
ing on the market using as a tool the potency of their
respective drugs to get more oocytes. Cancelling cycles
in which ovarian stimulation obtains a low number of
developing follicles has become a popular choice, espe-
cially in Countries in which the fierce competition
among IVF clinics is based on the pregnancy rate, and
thus it is inconvenient to go on with cycles in which a
poor oocyte yield is predictable. Furthermore, in Coun-
tries where either the public health system or the private
insurance system offer for free (or at very low costs)
only a limited number of attempts, the yield of at least a
dozen of oocytes is considered of great value by IVF
doctors and, as a consequence, by patients. Again, IVF
clinics running an oocyte donation program are particu-
larly satisfied when a patient produces enough eggs to
be treated herself and to give surplus oocytes to dona-
tion. More oocytes-more embryos-more pregnancies =
better IVF program: the most widely accepted principle
all over the IVF world.
However, it is out of discussion that the need of get-
ting a rather high number of oocytes arises from the
overall inefficiency of IVF laboratory procedure: several
oocytes are needed to finally get just a few embryos and
much less born babies. It is easy to calculate that the
live birth rate/inseminated oocyte is extremely low in
human IVF, on the average around 2-4%. Thus, the
complex and demanding ovarian stimulation protocols
are usually applied in order to compensate for the poor
laboratory effectiveness.
The IVF lab has indeed improved significantly in the
past three decades: new media and new equipment for
embryo culture have been made available on the market,
new scientific knowledge has been obtained. As a result,
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the overall efficiency of IVF procedure has markedly
improved from the 80’s until now: is it still necessary to
work on a high number of oocytes to get a baby?
Recruitment, selection and dominance of follicles
in ovarian physiology
The complete follicular development in humans takes
about 220 days and includes three distinct phases accord-
ing to the developmental stage and to the dependence
from pituitary gonadotropins: (a) initial recruitment of
resting primordial follicles, (b) development of preantral
and early antral follicles, (c) cyclic recruitment of a lim-
ited cohort of antral follicles followed by the selection of
a single dominant follicle [2]. Phases (a) and (b) are regu-
lated by a complex interplay of intra-ovarian factors and
are independent on gonadotropins. Phase (c) begins dur-
ing the luteal-follicular transition of the menstrual cycle,
when follicle-stimulating hormone (FSH) circulating
levels rise and increase over a threshold at which a cohort
of small antral follicles is recruited to grow [3].
The beginning of follicular growth is characterized by
morphological changes, including the proliferation of
granulosa cells, their change in shape, the enlargement
of the oocyte and the formation of the zona pellucida.
The early theca is acquired at the end of the primary
follicle stage, whereas the external theca forms as the
follicle grows and compresses the surrounding stroma
[3]. During the early preantral follicle development,
FSH, estrogen and androgen receptors appear on the
granulosa cell surface; however, at this stage, the follicle
is still unaffected by the lack of gonadotropins [2]. After
the initial rise, FSH blood levels plateau during the early
follicular phase and finally decrease during the mid-to-
late follicular phase as a consequence of the negative
feedback exerted by inhibin B and estrogens on the
hypothalamic-pituitary axis [2].
The presence of FSH is an absolute requirement for
the development of larger antral follicles [2]. Around
the mid-follicular phase, the most mature follicle (the
one with the highest number of FSH receptors on gran-
ulosa cells) gains dominance over the others; despite
progressively decreasing FSH blood levels, the dominant
follicle continues to grow and acquires responsiveness
to LH. The remaining follicles from the recruited cohort
undergo atresia and programmed cell death [1]. The
time during which FSH blood concentration is above a
given threshold appears to be essential for a single
dominant follicle selection (FSH window) [1].
The theorical concept at the basis of the “mild” stimu-
lation strategy is that a moderate but continued eleva-
tion of FSH during the mid-to-late follicular phase is
able to extend the FSH window and to overcome the
single dominant follicle selection, leading to the growth
of several follicles [2]. In the “mild” ovarian stimulation,
a low-dose gonadotropin administration is delayed until
the mid-follicular phase (day 2-to-5 of the cycle). The
aim is to allow initial follicle recruitment by endogenous
FSH, then prevent the decrease of FSH levels overcom-
ing dominance and inducing multi-follicular develop-
ment [1]. In women with a normal ovarian follicular
reserve, multiple follicle development can be induced
when the initiation of FSH is postponed until cycle
day 7, although there is a tendency toward a higher per-
centage of monofollicular responses compared with
patients starting on cycle day 2-to-5. A fixed daily dose
of 150 IU FSH is usually enough to induce multiple fol-
licular growth when ovarian stimulation is initiated on
cycle day 5 [4].
Conventional “long"protocols and the “mild”
stimulation approach
In the conventional “long” protocol, gonadotropins
(FSH, hMG or FSH+LH) are given to induce multiple
follicular development and a GnRH analogue is contem-
poraneously given to prevent the premature LH surge,
that would compromise the chance of retrieving oocytes
[5]. It took approximately 15 years of experience with
GnRH agonists to identify the optimal way to use them;
the best results were obtained starting GnRH analogue
administration in the mid-luteal phase of preceding
cycle, the so-called “long” protocol [6,7].
In the “long” protocol, GnRH agonist is started in the
luteal phase of the run-in cycle and continued until the
administration of hCG (ovulation trigger). An initial
flare of gonadotropin release (about 5 days) takes place
before the receptors are down-regulated and GnRH
action on the pituitary is blocked [6]. This protocol,
probably the most widely used throughout the world
even now, allows a quite good predictability of the work
in IVF Units, implies a low cancellation rate, and allows
to get a relatively high number of pre-ovulatory follicles,
of retrieved oocytes and, as a consequence, of embryos
available for transfer, thus leading to a satisfactory preg-
nancy rate [8].
However, the “long” protocol is associated with some
problems: several risks and complications have been
reported, the most important being ovarian hyperstimu-
lation syndrome (OHSS) in its severe form [9]. Hun-
dreds of patients are hospitalized every year because of
severe OHSS, which represents a life-threatening, high-
cost complication of human IVF. Moreover, the com-
plexity of the “long” protocol, entailing weeks of daily
injections and/or intra-nasal spraying, several blood
samples and frequent ovarian ultrasound scans for mon-
itoring, can impact on a woman’ s life, causing a high
rate of drop-out from IVF program [8].
The “mild” stimulation approach for IVF treatment is
aimed to develop more patient-friendly protocols in
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which the risks are minimized and the results are still
acceptable [8]. A “mild” IVF cycle is defined (ISMAAR
association) either as (a) a stimulation regimen in which
gonadotropins are administered at a lower-than-usual
dose and/or for a shorter duration throughout a cycle in
which GnRH antagonist is given as co-treatment, or (b)
a stimulation in which oral compounds (e.g. anti-estrogens)
are used either alone or in combination with gonadotro-
pins and GnRH-antagonists [10].
The key role of GnRH antagonists in “mild”
stimulation regimens
Although the use of GnRH antagonists is probably not
absolutely required for “mild” ovarian stimulation [11],
their introduction in the clinical practice has repre-
sented the key event to start using “mild” protocols in
IVF. The action of GnRH antagonists is characterized by
an immediate suppression of the pituitary release of
gonadotropins and by a rapid recovery of normal gona-
dotropin secretion when the drug is withdrawn [6]. The
mid-cycle LH surge requires the secretion of native
GnRH and can therefore be effectively prevented by
GnRH antagonist administration. The immediacy of
action of GnRH antagonists allows to block the pituitary
just when the circulating estradiol rise approaches the
threshold level at which LH surge is generated by the
positive feedback loop on the pituitary. At the beginning
of stimulation cycle; ovarian stimulation can be initiated
by endogenous gonadotropins with a normal early folli-
cular phase recruitment of a cohort of follicles, without
any pituitary block [6].
In the last years, three general approaches for the
GnRH antagonist co-treatment in IVF have emerged: (a)
inject a single large dose subcutaneously on approxi-
mately the eighth day of stimulation with gonadotropins,
(b) give daily injections of small doses initiated on a
fixed day of stimulation (fixed protocol), or (c) give daily
injections of small doses initiated depending on the size
of the dominant follicle or on estradiol levels (flexible
protocol) [6]. Administration regimens (b) and (c) are
continued until the day in which hCG is given to obtain
the final oocyte maturation.
The introduction of GnRH-antagonists in the clinical
IVF workout has been characterized by a long learning
curve (probably still ongoing) and by several perplexities
on their effectiveness. Initially, large prospective trials
comparing ovarian stimulation with the “long” agonist
protocol vs. a daily antagonist protocol (in which high
gonadotropin doses were used) revealed the latter to
generate fewer follicles and fewer oocytes; oocytes and
embryos were of equivalent morphological quality, but
finally an average decrement in pregnancy rate of 5%
was observed in the antagonist cycles [12]. The better
pregnancy rate in the agonist cycles was felt to be due
to the larger oocyte availability, allowing to obtain more
embryos and to better select those worth to be trans-
ferred in utero or cryopreserved [13]. Moreover, in the
initial dose-finding studies on GnRH antagonists an
inverse relationship between antagonist dose and
implantation rate was observed, suggesting a potential
toxic effect of the drug on embryos and/or on the endo-
metrial receptivity [13]. After these early reports were
published, the protocols with GnRH antagonists became
for many clinicians a second choice; this is proven by
the analysis of the German IVF registry from 2000 to
2003, that clearly shows that GnRH antagonists were
often utilized in cycles with unfavourable a priori prog-
nosis (e.g. patients with advanced reproductive age and/
or with several previously failed IVF attempts) [14].
GnRH antagonists began to be revaluated when the sub-
analysis of patients with equal demographic and clinical
features was performed on the same database: similar
pregnancy rates were found independent of whether
GnRH agonist or antagonist had been used [15].
Further, although the initial five large randomized con-
trolled trials (RCTs) comparing GnRH antagonists vs.
agonists showed a 5% difference in the chance of clinical
pregnancy in favour of the agonists, the difference in
live birth rate (still in favour of agonists by 3.8%) was
not statistically significant [16]. A later meta-analysis
including 22 RCTs published between 2000 and 2005
and including much more patients (3176 women) found
a live birth rate reduced by -2.7% in the antagonist-trea-
ted group, still not statistically significant even when
data were subdivided and re-analysed according to the
type of population, the type of gonadotropin used, the
type of agonist and antagonist [16]. Differently, the
Cochrane Review including 27 RCTs (3865 patients),
observed significantly lower clinical and ongoing preg-
nancy rates in women treated with antagonists (OR
0.84, 95% CI = 0.72-0.97 and OR 0.82, 95 CI 0.69-0.98
respectively) [17], but still these results could be inter-
preted as due to the learning curve needed to optimize
protocols with antagonists, similarly to what happened
when agonists were made available on the market.
IVF results in “mild” stimulation protocols vs.
classical “long” protocol
At present, the “long” GnRH-agonist regimen with rela-
tive high doses of exogenous gonadotropins is probably
the most frequently used stimulation protocol; this regi-
men has become a comfortable routine over the years in
many IVF clinics. In the last years, the availability of
GnRH antagonists has allowed the clinical development
of “mild” ovarian stimulation protocols involving subtle
interference with single dominant follicle selection.
Some studies have compared the success rate of “mild”
vs. standard ovarian stimulation regimens, either in
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women with normal ovarian reserve or in subjects with
poor ovarian reserve.
Women with normal ovarian reserve
Three prospective, randomized controlled trials com-
pared the effectiveness of “mild” stimulation regimen
with the conventional “long” GnRH agonist protocol
with an early follicular phase FSH start.
The single centre RCT by Hohmann et al. [18] included
142 patients with good reproductive prognosis who were
randomly distributed into three groups: (A) (n= 45) trea-
ted with the GnRH-agonist Triptorelin and, after down-
regulation, with a fixed daily dose of 150 IU rFSH; (B)
(n= 48) and (C) (n= 49) treated with rFSH initiated on
cycle day 2 (group B) or 5 (group C) and with the GnRH-
antagonist Cetrorelix starting when the largest follicle
reached 14 mm diameter. Group C showed a shorter
duration of stimulation, reflected in a significantly lower
total dose of exogenous rFSH; in group C, more cycles
were cancelled due to insufficient response and less
oocytes were harvested, but better quality embryos were
finally obtained. Fewer cycles in group C were character-
ized by a total fertilization failure or by abnormal embryo
development. Nevertheless, because of the higher num-
ber of oocytes retrieved in group A and B and to the bet-
ter availability of embryos among which selecting the
best, no significant difference in the quality of the best
transferred embryo was observed among the three
groups. After stronger ovarian stimulation (groups A and
B), only 7% of the patients who retrieved less than 5
oocytes conceived, whereas after “mild” stimulation 67%
of these patients conceived. Overall, no differences were
found among the three groups as far as the pregnancy
rate per started cycle was concerned.
The results of this study suggest that a low number of
retrieved oocytes after “mild” ovarian stimulation could
have a different meaning from a low number of
retrieved oocytes after a conventional stimulation. It was
shown that the ideal number of oocytes after a conven-
tional “long” protocol is 13 and that when the number
of retrieved eggs is much lower (or even much higher),
the pregnancy rate is compromised [19]. A poor oocyte
yield after classical ovarian stimulation likely reflects a
poor ovarian responsiveness to FSH, that is associated
with poor IVF outcome, whereas a low number of
oocytes after “mild” stimulation probably represents a
normal response, a smoother selection of follicles (and
oocytes) more likely to finally result in high quality
embryos and in a pregnancy [20]. A low overall dose of
exogenous FSH probably stimulates only the most
mature follicles having optimal receptor endowment,
and allows a sort of “quality selection” among follicles
(and finally among oocytes) avoiding to force poor qual-
ity follicles to grow anyway [20].
Another RCT by Heijnen et al. [21] included 404
regularly cycling, normal BMI patients and almost 800
consecutive IVF cycles. In this study, one group was
given “mild” ovarian stimulation with GnRH antagonist
co-treatment combined with selected single embryo-
transfer (SSET), whereas the other received a standard
ovarian stimulation with the GnRH agonist “long” pro-
tocol combined with the transfer of two embryos. The
“mild” treatment group was characterized by a lower
duration of stimulation, a lower total FSH dose and by
less retrieved oocytes. The pregnancy rate per cycle was
significantly lower in the “mild” stimulation group
(17.6% vs 28.6%, p < 0.0001); however, the “mild” stimu-
lation protocol, easier to stand and cheaper for patients,
reduced the rate of treatment discontinuation and
induced some patients to undergo shortly a second IVF
attempt. This attitude resulted in a cumulative live birth
rate after 1 year of IVF treatments that was comparable
in the two groups (43.4% with the mild protocol, 44.7%
with the standard regimen), and the twinning rate was
significantly lower in the “mild” stimulation-SSET trans-
fer group (0.5% vs. 13.1%, p < 0.0001) [21]. According
to this study, a reduced chances of birth per cycle in the
“mild” regimen might be compensated by the increased
number of IVF attempts in a set time. In fact, the over-
all discomfort to patients, evaluated with the hospital
anxiety scale, the depression scale, the somatic Hopkins’
subscale and the subjective sleep quality scale, were
lower in the group assigned to the “mild” stimulation.
Interestingly, also the economical costs of the treatment
were significantly lower with the mild stimulation/SSET
compared with a standard treatment involving conven-
tional stimulation; it must be remarked, however, that
the money saving was mainly due to the almost com-
plete absence of twin pregnancies in the “mild” group
rather then to the cost of IVF procedure itself [21].
Interestingly, a prediction model aimed to estimate the
chance of ongoing pregnancy after “mild” stimulation
and SSET has been prepared using multivariate logistic
regression analysis; this model is claimed to be helpful
to optimize results identifying patients for which the
“mild” stimulation plus SSET strategy can be appropri-
ate [22].
The third RCT comparing the “mild” protocol and the
“long” classical protocol was performed by Baart et al
[23] on 111 patients who were randomized into two
groups, one (n = 67) receiving rFSH 150 IU/day from
day five of the cycle plus GnRH-antagonist in a flexible
schedule, the other (n = 44) receiving rFSH 225 IU/die
after two weeks of pituitary down-regulation by GnRH-
agonist. In this study, couples with severe male factor
were excluded. The ongoing pregnancy rate per started
cycle was 21% in the “mild” group and 18% in the con-
trol group, a difference not statistically significant.
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Interestingly, in this study embryos were biopsied at the
8-cells stage and 1 or 2 blastomeres were then analyzed
by fluorescent in-situ hybridization (FISH) considering
10 chromosomes: despite “mild” stimulation obtained
significantly fewer oocytes and embryos, both regimens
finally generated the same number (1.8/cycle) of chro-
mosomically normal embryos. This observation suggests
that the reduced pharmacological interference with
ovarian physiology could generate oocytes of better
genetical quality. Indeed, some data in the mouse model
show that exogenous disturbances in the signals regulat-
ing folliculogenesis may alter the late stage of oocyte
growth, increasing the risk of altered chromosome seg-
regation in subsequent meiotic divisions: an increased
incidence of chromosomal abnormalities, in fact, was
observed in oocytes after exposure to high doses of
gonadotropins during in vitro maturation of mouse
oocytes [23,24]. Mild stimulation approaches, aiming at
a more physiological response, might be able to improve
the genetical quality of oocyte and embryos in humans.
This hypothesis, however, needs to be validated by
further trials including a higher number of patients and
embryos, and possibly using techniques (e.g. CGH) able
to study the whole set of chromosomes on a single
blastomere.
Taken together, these three RCTs comparing the
“mild” with the classical stimulation regimen included
592 first IVF attempts, among which 313 were per-
formed with the “mild” stimulation protocol and 279
with the classical “long” regimen. Although individually
these trials found comparable results in terms of IVF
effectiveness, pooling data together the ongoing preg-
nancy rate per started cycle sorts out to be 15% in the
“mild” group and 29% in the classical group, a difference
that suggests a well definite trend toward a lower IVF
effectiveness when the “mild” strategy is applied. This
suggestion is further reinforced by the fact that the
three RCTs did not consider freeze-thaw cycles, and the
chance of obtaining surplus embryos/oocytes to freeze is
obviously much lower in “mildly” stimulated cycles than
in the classical ovarian stimulation cycles. Having frozen
embryos/oocytes to transfer in a subsequent cycle can
probably increase the overall IVF pregnancy chance per
oocyte pick-up by approximately 10-15%: thus, the gap
between the two competitors could probably be wider
considering freeze/thawing cycles, and could possibly
reach statistical significance. New RCTs including
freeze-thaw cycles in the comparison between “mild”
and classical stimulation regimens are definitely needed
to get a higher level of evidence about the respective
effectiveness of the two strategies.
A factor limiting the effectiveness of “mild” strategy in
terms of pregnancy rate per cycle is likely to be the rela-
tively high rate of cycle cancellation due to mono- or
bi-follicular response (around 15-20%) when gonadotro-
pins are started on day 5 of the cycle. When such a
response is observed, a valuable option is to stop stimu-
lation and start it again the next month starting earlier
with medications (on day 2-4). Ovarian aging and high
BMI have been identified as relevant variables to predict
the risk of insufficient response to “mild” stimulation,
and a predictive model have been developed in order to
minimize the need of cancelling the cycle [25].
On the other side, classical ovarian stimulation is
claimed to be a factor able to impair endometrial
maturation and consequently embryo implantation
chance. Some studies indeed showed that the gene
expression profiling of the endometrium in convention-
ally stimulated cycles is extremely different from the
one that can be observed during a natural cycle [26,27]:
interestingly, the endometrial gene expression pattern is
more similar to the natural one in cycles with GnRH-
antagonists than in cycles with GnRH-agonists [28].
Furthermore, classical ovarian stimulation regimens are
associated with about ten-folds supra-physiological cir-
culating estradiol levels that have a well documented
negative impact on the developmental and implantation
potential of human embryos [24,29]. Some data suggest
that the best endometrial receptivity to embryo implan-
tation may be found in natural cycle, but mild stimula-
tions have a lower impact on endometrial quality than
classical regimens [30,31]. The “mild” stimulation regi-
men is associated with significantly lower peak estradiol
levels, and possibly can impact on the endometriom
more softly than classical regimens: the “endometrial
factor” can probably represent one scored point in
favour of “mild” stimulation.
Women with poor ovarian reserve
Ovarian stimulation for women with a poor ovarian
reserve is probably one of the most frustrating aspects
of IVF procedure: most of the treatments proposed to
enhance oocyte yield and pregnancy rates in “poor”
responders have failed to show any convincing evidence
[32].
The standard approach to women estimated to be
poor responders is based on starting the “long” protocol
with a daily dose of approximately 300 FSH IU/die [33];
the starting FSH dose used in any subsequent cycle is
then adjusted (up to 600 FSH IU/die) according to the
individual response in the first cycle [34]. The strategy
of performing an upward dose adjustment in women
with poor ovarian reserve, however, has not shown any
consistent benefit. In previous poor responders, in fact,
the IVF outcome of those assigned to a starting dose of
225 FSH UI/day vs. those receiving 450 UI/day was
shown to be similar, despite the latter obtained more
oocytes [35]. Also other studies showed that predicted
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poor responders had no benefit from increasing the FSH
starting dose [36,37]. High gonadotropin doses may
indeed lower the cycle cancellation rate, but have been
observed to reduce the likelihood of clinical pregnancy
and live birth rate and to increase the risk of sponta-
neous miscarriage [38]. A negative effect of high dose
regimens on the endometrial quality has been claimed
to be responsible for the poor outcome of this regimen
[39], although probably even factors linked to embryo
quality itself play a relevant role. High doses of FSH
recruit “resistant” follicles rescuing them from atresia,
but the oocytes that they host are of poor quality and
usually do not result in the generation of good quality
embryos [40,41]. Since the economical cost of gonado-
tropins is one of the major expenditures in IVF treat-
ment, the huge increase in drug cost linked to high-dose
gonadotropin regimens appears to be a nonsense if not
paralleled by a significant improvement in clinical
outcome.
A combination of Clomiphene citrate (CC) plus gona-
dotropins and GnRH antagonists has been proposed as
a “mild” stimulation alternative for poor responders. CC
is known to act as an anti- estrogen on the central ner-
vous system, increasing the pulse frequency of endogen-
ous FSH and LH and giving a moderate gonadotropin
stimulus to the ovary [42]. CC has been used for over
thirty-five years to induce ovulation in WHO type II
anovulatory women, and is still appreciated for its oral
administration and low price; the combination with
gonadotropins may counterbalance its undesired anti-
estrogenic effect on the endometrium and at the same
time may reduce the amount of gonadotropins required,
thanks to the combined synergistic effect on the ovary.
The level of evidence supporting the use of the “mild”
stimulation protocol with CC/Gn/GnRH antagonist in
patients with poor ovarian reserve is rather poor, as
properly designed studies on an appropriate number of
patients are still unavailable. The first report describing
the use of CC/Gn/GnRH antagonists in poor responders
included only eighteen patients; compared to their
response in a previous standard GnRH-agonist cycle,
light improvements in cycle cancellation rate, oocyte
yield and gonadotropin requirement were observed [43].
Unfortunately, neither the number of patients, nor the
study design allowed to get an acceptable level of
evidence.
Takahashi et al. [44] studied 40 poor responders with
a story of multiple IVF failures with the “long” protocol:
treating them with CC/FSH/GnRH antagonist he
obtained an ovarian response comparable to the pre-
vious ones, but a significantly higher blastocyst develop-
ment rate and a very good (41.2%) ongoing pregnancy
rate. Again, the study design was not very informative
and the patient number was too little.
D’Amato et al [45] compared the combination of CC/
FSH/GnRH antagonist to a long GnRH agonist protocol
enrolling 145 women with a prior poor response; a signifi-
cantly lower cancellation rate, higher peak oestradiol level,
more retrieved oocytes and higher pregnancy and implan-
tation rates were achieved with the antagonist protocol. In
this study, however, high FSH amounts and not a “mild”
gonadotropin stimulation were used: the observations,
once again, are only indicative of the possibility of using
this kind of stimulation at lower doses in poor responders.
Some other informations may be deduced from studies
that compared the outcome of CC/Gn/GnRH antagonist
treatment with a standard “long” protocol in patients
with normal ovarian reserve: pregnancy rates comparable
to the standard stimulation regimens were obtained by
the “mild” strategy, with a significant reduction in the
total dose of gonadotropin needed and of the economical
costs [46-48]. These results appear to be encouraging,
although it remains to be proven that they can be repli-
cated even with patients with poor ovarian reserve.
Interestingly, it was shown that when in CC/Gn/
GnRH antagonist cycles the circulating level of LH is
less than one-third at the time of hCG than it was at
the beginning of stimulation, both the pregnancy and
implantation rates are significantly reduced [49]: this
observation suggests to chose medications containing
LH or hCG rather than FSH alone to be associated with
CC in this kind of protocol.
Overall, the published results suggest that in patients
with poor ovarian reserve the choice of a mild stimula-
tion protocol instead of a classical, high dose regimen,
could be particularly indicated. Although these patients
have a very low risk of OHSS even using high doses, the
quality of both their oocytes and their endometrium
could likely to be better when a smoother stimulation
approach is used. Further research, anyway, is needed to
add scientific evidence to this hypothesis.
Other aspects to be considered
Risk of ovarian hyperstimulation syndrome (OHSS)
It is well known that IVF treatment exposes women to
the risk of short-term complications, among which the
severe form of OHSS is the most important. Severe
OHSS is a serious and potentially life-threatening com-
plication of IVF whose symptoms are very well known,
and has a mean incidence of 1-3% in IVF programs
involving standard ovarian stimulation regimens [50].
Some patients are definitely considerable at high risk:
young, lean women with polycystic ovaries (PCO) are a
typical example; their risk of developing severe OHSS
after a conventional ovarian stimulation for IVF is
around 6-9% for a young PCO patient.
The incidence of severe OHSS is significantly lower when
GnRH antagonists are used instead of agonists [16,17],
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probably due to the smaller cohort of recruited follicles
and to the lower circulating estradiol levels during ovar-
ian stimulation. The meta-analysis of Kolibianakis found
that the incidence of hospital admission for OHSS is sig-
nificantly lower in GnRH antagonist cycles than in ago-
nist cycles (OR 0.46;95% CL 0.26-0.82; P = 0.1) [16]. Also
the Cochrane review by Al-Inany reported that the inci-
dence of severe OHSS is significantly lower in protocols
with GnRH antagonists than in protocols with GnRH
agonists (RR 0.61; 95% CI 0.42-0.89; P = 0.01); moreover,
secondary methods to prevent OHSS (such as coasting or
cycle cancellation) need to be used more frequently dur-
ing the GnRH-agonist cycles (OR 0.44;95% CI 0.21-0.93;
P 0.03) [17]. Further, the risk of severe OHSS is reduced
until around zero if ovulation trigger is elicited using a
single dose of GnRH agonist instead on hCG: this is pos-
sible if a stimulation with GnRH antagonists has been
applied, and an endogenous LH peak can be obtained sti-
mulating the pituitary [51].
The risk of developing severe OHSS is further signifi-
cantly reduced using “mild” stimulation regimens; in the
study of Heijnen [21] the incidence of OHSS was 1.4% with
the mild protocol and 3.7% with the long protocol. In
another study, Karimzadeh et al. [46] observed a zero inci-
dence of OHSS in the group treated with “mild” stimulation
vs. 6% in the group treated with conventional stimulation.
Risk of long term health problems
The discussion about long-term health consequences of
ovarian stimulation for IVF, especially concerning the
association between hormones and cancer, is far from
being concluded. The epidemiological studies published
so far in humans remain inconclusive, due to a huge
amount of confounders and to a relatively short follow-
up period of time [52,53].
Although gonadotropin treatment is not considered
oncogenic, nor able to significantly affect the patient’s
chance of having serious diseases, it appears safer to use
the lowest dose possible of hormons, expecially in case
of repeated IVF attempts.
Emotional stress
Emotional stress represents a well known negative side
effects associated with IVF treatment, and probably one
of the most important reasons for dropping out of the
program.
Some studies suggest that women who receive milder
approaches in ovarian stimulation could be more prone
to face a new treatment attempt compared with women
receiving a standard protocol: in fact, the psychological
burden of treatment is one of the most frequent causes
of drop-out, and a significantly lower drop-out rate was
observed in more patient-friendly “mild” stimulation
programs [22,54]. The lower incidence of the so-called
minor symptoms (abdominal pain, nausea, etc.) that can
be associated with conventional ovarian stimulation pro-
tocols is probably a factor that increases the patients’
attitude to repeat IVF, as it has a lower daily impact on
the quality of life. A better predisposition to repeat the
treatment after a failed attempt may obviously have a
positive impact on the cumulative treatment success
rate and could eventually compensate for a lower preg-
nancy rate per cycle following “mild” stimulation.
On the other side, however, the lower pregnancy
chance per attempt with the “mild” approach can be
itself a reason of emotional stress. Treatment failure, in
fact, is associated with a deterioration of emotional well
being [55], subclinical depression [56] and/or anxiety
[57]. Furthermore, one of the most stressing events in
an IVF cycle is oocyte retrieval, either preformed under
general or local anaesthesia; if a stimulation strategy
gets lower “per cycle” results, patients will be more fre-
quently forced to repeat oocyte retrieval, with a possible
increase of emotional stress.
Some studies comparing the conventional ovarian sti-
mulation with the “mild” regimen failed to observe a dif-
ference in the anxiety or depression levels, or on sleep
quality [21,58].
Overall, the evidence about a possible psychological
benefit of “mild” protocols is still inconclusive. Even
when looking at the patient’s emotional well-being, a
careful balance between the daily physical problems of
stimulation and the overall effectiveness of IVF treatment
must be carefully considered, discussing with each single
couple pro and contra of the choice of a specific protocol.
Economical costs
A milder ovarian stimulation is undoubtedly associated
with a lower medication consumption and with a lower
cost for purchasing drugs. A couple of studies showed
the superiority of the “mild” stimulation strategy over the
standard approach in terms of economical costs [21,59],
especially when the “mild” strategy includes SSET [21].
Once again, however, the balance between lower costs
and lower “per cycle” results must be carefully considered:
if IVF effectiveness is under a critical threshold, the fre-
quent need to repeat treatment (even several times) leads
to new economical costs for the patient. This could repre-
sent a concrete problem particularly for people living in
those countries where patients pay for their own treatment
or the public health/private insurance systems give for free
(or at very low costs) only a limited number of attempts.
The convenience of adopting the “mild” stimulation strat-
egy in developing “third world” Countries has not yet been
convincingly demonstrated.
The lower effectiveness of IVF procedure can also
become a problem for IVF clinics choosing the “mild”
strategy, who will compete on the market with clinics
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following classical stimulation concepts; if the clinic
loses patients for the lower “per cycle” effectiveness of
its IVF program, it could be forced to go back to classi-
cal stimulations or, alternatively, to increase prices,
finally weighting on patients’ budget.
Conclusions
In the last decades, several steps have been done with the
aim of rendering human IVF more and more successful
on one side, more and more tolerable and easy to perform
on the other side. IVF programs are now totally feasible
on an outpatient, office basis: no hospitalization or general
anaesthesia are needed, and patients more or less keep on
with their normal life during treatment. Anyway, a consid-
erable proportion of women still experience discomfort
and emotional stress, and some of them face relevant (or
even serious) health complications. Moreover, IVF is still a
very expensive treatment, especially considering its limited
success rate that often forces to repeated attempts and the
higher chance of having a twin pregnancy with all its
obstetrical and neonatal complications.
The mild stimulation approach, especially when linked
to selected single embryo transfer, may represent an
important step toward the objective of an easier IVF,
more tolerable and problem-free for patients, cheaper
for both patients and the society, but still having an
acceptable effectiveness in terms of baby birth rates.
Effectiveness is actually the core of discussion when
dealing with “mild” stimulation strategy. To date, too
few properly designed studies are available to allow a
scientific, conclusive judgement. What is definitely
needed is a series of RCTs comparing, in different sub-
sets of IVF patients, “mild” stimulation protocols with
the conventional GnRH agonist protocols or, alterna-
tively, with stimulation regimens using GnRH antago-
nists with high gonadotropin doses. To be fully
informative, these studies should come from different
research groups and should be properly weighted and
designed, involving also freeze-thaw cycles.
The need for an OHSS-free IVF program is felt as a
key issue by most IVF doctors and represents one of the
objectives of many IVF Units. Further research is needed
to find ideal ovarian stimulation protocols able to obtain
high quality oocytes, optimal IVF success rates even in
poor-prognosis patients and in the meanwhile able to
reduce undesirable effects and complications. The
“mild” stimulation philosophy is interesting, but its true
effectiveness as well as its impact on emotional and eco-
nomical aspects of IVF must be further investigated.
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